This phase 3 FRAME trial tested romosozumab, a sclerostin-inhibiting antibody, in postmenopausal women with osteoporosis. Women received monthly romosozumab or placebo for 12 months, then all transitioned to denosumab for a second year. The question: does inhibiting sclerostin reduce fracture risk in osteoporosis?
Romosozumab works by a mechanism distinct from bisphosphonates: it inhibits sclerostin, the osteocyte-secreted brake on Wnt signaling, so it builds bone AND blocks resorption at the same time. This dual action explains the rapid, large BMD gains (+13.3 points at the spine in one year) and the fast vertebral fracture reduction, with benefit apparent by 6 months.
A key teaching point is the anabolic-then-antiresorptive strategy: gains from romosozumab must be locked in with a follow-on agent like denosumab, or they are lost. Never leave an anabolic course untreated afterward.
Critically appraise the nonvertebral endpoint: it failed to reach significance (P=0.10), partly because the Latin American cohort had an unexpectedly low placebo fracture rate and low baseline FRAX scores. Remember the class-associated risks: atypical femoral fracture and osteonecrosis of the jaw, though rare here and confounded.
This phase 3 FRAME trial tested romosozumab, a sclerostin-inhibiting antibody, in postmenopausal women with osteoporosis. Women received monthly romosozumab or placebo for 12 months, then all transitioned to denosumab for a second year. The question: does inhibiting sclerostin reduce fracture risk in osteoporosis?
Romosozumab works by a mechanism distinct from bisphosphonates: it inhibits sclerostin, the osteocyte-secreted brake on Wnt signaling, so it builds bone AND blocks resorption at the same time. This dual action explains the rapid, large BMD gains (+13.3 points at the spine in one year) and the fast vertebral fracture reduction, with benefit apparent by 6 months.
A key teaching point is the anabolic-then-antiresorptive strategy: gains from romosozumab must be locked in with a follow-on agent like denosumab, or they are lost. Never leave an anabolic course untreated afterward.
Critically appraise the nonvertebral endpoint: it failed to reach significance (P=0.10), partly because the Latin American cohort had an unexpectedly low placebo fracture rate and low baseline FRAX scores. Remember the class-associated risks: atypical femoral fracture and osteonecrosis of the jaw, though rare here and confounded.